About: Patented Medicine Prices Review Board     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : dbo:Organisation, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FPatented_Medicine_Prices_Review_Board

The Patented Medicine Prices Review Board (French: Conseil d'examen du prix des médicaments brevetés) is a federal quasi-judicial regulatory and reporting agency in Canada with a mandate to protect consumers by ensuring that the prices of patented medication charged by manufacturers of patented drugs are not excessive. The board does this through its role as a regulator, and through its reporting on trends, research and development in the Canadian pharmaceutical industry.

AttributesValues
rdf:type
rdfs:label
  • Patented Medicine Prices Review Board (en)
rdfs:comment
  • The Patented Medicine Prices Review Board (French: Conseil d'examen du prix des médicaments brevetés) is a federal quasi-judicial regulatory and reporting agency in Canada with a mandate to protect consumers by ensuring that the prices of patented medication charged by manufacturers of patented drugs are not excessive. The board does this through its role as a regulator, and through its reporting on trends, research and development in the Canadian pharmaceutical industry. (en)
foaf:homepage
name
  • Patented Medicine Prices Review Board (en)
foaf:depiction
  • http://commons.wikimedia.org/wiki/Special:FilePath/PMPRB_logo.svg
location
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
thumbnail
budget
  • CA$10.3 million (en)
employees
headquarters
jurisdiction
logo
  • PMPRB logo.svg (en)
native name
  • (en)
website
has abstract
  • The Patented Medicine Prices Review Board (French: Conseil d'examen du prix des médicaments brevetés) is a federal quasi-judicial regulatory and reporting agency in Canada with a mandate to protect consumers by ensuring that the prices of patented medication charged by manufacturers of patented drugs are not excessive. The board does this through its role as a regulator, and through its reporting on trends, research and development in the Canadian pharmaceutical industry. The board investigates, reviews and negotiates the price of individual drugs that are still under patent and which have no generic substitutes. It establishes the maximum prices that can be charged in Canada for patented drugs. (en)
chief1 name
  • Mitchell Levine (en)
chief1 position
  • Chairperson (en)
chief2 name
  • Mélanie Bourassa Forcier (en)
chief2 position
  • Vice-chairperson (en)
chief3 name
  • Douglas Clark (en)
chief3 position
  • Executive Director (en)
keydocument
  • Patent Act (en)
minister1 name
minister1 pfo
gold:hypernym
schema:sameAs
prov:wasDerivedFrom
page length (characters) of wiki page
jurisdiction
budget ($)
formation year
number of employees
headquarter
leader
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (62 GB total memory, 52 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software